A
Aptevo Therapeutics Inc.
APVOCIK 0001671584NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
—
Total Assets
$27.19M
Equity
$17.38M
Shares Out
1.18M
Op. Cash Flow
$-25.60M
Business
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on discovery and development of novel immunotherapies that modulate the immune system to treat hematologic malignancies and solid tumors. Its main products include ADAPTIR and ADAPTIR-FLEX–derived therapeutics, with clinical candidates mipletamig (a CD3xCD123 T‑cell engager) and ALG.APV-527 (a 4‑1BB x 5T4 bispecific), and preclinical candidates APVO603, APVO442 and APVO711. The company operates research and development and platform technology segments and pursues collaborations and licensing arrangements (e.g., with Alligator Bioscience). It advances programs through multi‑center clinical trials and seeks commercialization via partnerships and regulatory approvals in the U.S. and international markets.
Summary from filing dated 2025-02-14
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | −15 | −14 | −17 | −18 | −19 | |
| General and administrative | −12 | −10 | −12 | −14 | −15 | |
| Loss from operations | −26 | −25 | −29 | −29 | −21 | |
| Other income, net | 345,000 | 472,000 | 578,000 | −4 | −8 | |
| Net loss | −26 | −24 | −19 | 7 | −29 | |
| Dividend attributable to down round feature of warrants | −2 | — | — | — | — | |
| Net loss attributable to common stockholders | −28 | −24 | — | — | — | |
| Basic net loss per share | −87.27 | −31,460 | −2,317 | 1.57 | −6.07 | |
| Diluted net loss per share | −87.27 | −31,460 | −2,317 | 1.57 | −6.07 | |
| Basic shares used in calculation | 315,535 | 767 | 7,515 | 5 | 5 | |
| Diluted shares used in calculation | 315,535 | 767 | 7,515 | 5 | 5 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-05-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 22 | 9 | 17 | 23 | — | |
| Prepaid expenses and other current assets | 1 | 2 | — | — | — | |
| Total current assets | 23 | 11 | 19 | 27 | — | |
| Property and equipment, net | 303,000 | 543,000 | 895,000 | 1 | — | |
| Operating lease right-of-use asset | 4 | 4 | 5 | 5 | 4 | |
| Total assets | 27 | 16 | 25 | 34 | — | |
| Accounts payable | 877,000 | 1 | — | — | — | |
| Accrued expenses and other current liabilities | 4 | 4 | — | — | — | |
| Operating lease liability, current portion | 900,000 | 800,000 | — | — | — | |
| Total current liabilities | 6 | 6 | 7 | 9 | — | |
| Operating lease liability, net of current portion | 4 | 5 | 5 | 6 | — | |
| Total liabilities | 10 | 11 | 13 | 16 | — | |
| Preferred stock: $0.001 par value; 15,000,000 shares authorized, zero shares issued or outstanding | — | — | — | — | — | |
| Common stock: $0.001 par value; 500,000,000 shares authorized; 997,830 and 4,051 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 114,000 | 84,000 | 61,000 | 48,000 | — | |
| Additional paid-in capital | 292 | 252 | 236 | 224 | — | |
| Accumulated deficit | −275 | −248 | −223 | −206 | — | |
| Total stockholders' equity | 17 | 5 | 12 | 18 | — | |
| Total liabilities and stockholders' equity | 27 | 16 | 25 | 34 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −26 | −24 | −17 | 8 | −28 | |
| Stock-based compensation | 96,000 | 1 | 2 | 2 | 2 | |
| Non-cash lease expense | 1 | 1 | — | — | — | |
| Depreciation and amortization | 240,000 | 352,000 | 567,000 | 901,000 | 1 | |
| Prepaid expenses and other current assets | 483,000 | 217,000 | 153,000 | 355,000 | 436,000 | |
| Accounts payable, accrued compensation, accrued expenses and other current liabilities, and short-term operating lease | −157,000 | −1 | 518,000 | −394,000 | −2 | |
| Operating lease liability | −1 | −1 | — | — | — | |
| Net cash used in operating activities | −26 | −24 | −12 | −21 | −22 | |
| Net cash from investing activities | 0 | 0 | 0 | −29,000 | −713,000 | |
| Value of equity awards withheld for tax liability | 0 | −1,000 | −10,000 | −4,000 | — | |
| Proceeds from exercise of common warrants, net of issuance costs | 557,000 | 6 | 3 | — | 1 | |
| Proceeds from issuance of common stock, pre-funded warrants exercise, and common warrants exercise, net of issuance costs | 38 | 10 | 6 | 7 | 10 | |
| Payments in lieu of fractional shares | — | −3,000 | — | — | — | |
| Net cash provided by financing activities | 38 | 16 | 6 | −3 | 26 | |
| Increase (decrease) in cash and cash equivalents | 13 | −8 | −6 | −24 | 4 | |
| Warrant modification - incremental value | 586,000 | 472,000 | 2 | — | — | |
| Fair value of December 2024 inducement transaction common warrants | — | 7 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro